The $42B Samsung Biogen deal is too cheap, says Oppenheimer Health Care analyst Holz

Jared Holz, Oppenheimer Health Care analyst, joins 'Fast Money' to discuss reports that Samsung may be in talks to buy Biogen for $42 billion deal.